We found that METTL3 mediates the m6A modification of AKT1‐mRNA, leading to increased AKT1‐mRNA and protein expression, which renders MSCs more likely to differentiate into adipocytes, thus changing the BMM and causing changes in AML chemoresistance (Fig. 6). The gene discussed is AKT1; the disease is acute myeloid leukemia.